• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

ChromoTek FITC Plus-conjugated PD-L1 VHH

FITC-pdlo targets PD-L1 in FC and IF applications and shows reactivity with Human samples.

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

FITC Plus Fluorescent dye

Cat No : FITC-pdlo

Synonyms

PD-L1-Nanobody, PD-L1-Single domain antibody (sdAb), B7 homolog 1, B7-H1, CD274, programmed cell death 1 ligand 1, PDL1, PD-L1

Validation Data Gallery

  • 1X10^6 HEK PD-L1 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg FITC Plus conjugated-PD-L1 VHH (FITC-pdlo). Cells were not fixed.

    1X10^6 HEK PD-L1 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg FITC Plus conjugated-PD-L1 VHH (FITC-pdlo). Cells were not fixed.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) and CL750 CD3 (CL750-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) and CL750 CD3 (CL750-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated PD-L1 VHH (FITC-pdlo) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

  • A431 cells transfected with human PD-L1 were immunostained with FITC Plus conjugated-PD-L1 VHH (FITC-pdlo) (1:1000, green). Nuclei were stained with DAPI (blue). Epifluorescence images were acquired with a 20x objective and post-processed. Comment: Immunostaining with FITC-pdlo can be performed live or after formaldehyde fixation.

    A431 cells transfected with human PD-L1 were immunostained with FITC Plus conjugated-PD-L1 VHH (FITC-pdlo) (1:1000, green). Nuclei were stained with DAPI (blue). Epifluorescence images were acquired with a 20x objective and post-processed. Comment: Immunostaining with FITC-pdlo can be performed live or after formaldehyde fixation.

Product Information

FITC-pdlo targets PD-L1 in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateFITC Plus Fluorescent dye
TypeNanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight13.887 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
RRIDAB_3661837
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundPD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. D-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).

Documentation

SDS
SDS-Immuno-Oncology VHHs